Rhythm Biosciences Ltd has released a press release.
Product and Market Update - Phase 2 Milestone
Filed with ASX ·
6ix hasn’t read this filing yet.
Rhythm Biosciences Limited on 6ix
Story so far
Earlier from Rhythm Biosciences
- Jun 24 Quarterly Activities Report and Appendix 4C
- Mar24 Quarterly Activities Report and Appendix 4C
- Dr David Atkins appointed Chief Executive Officer of Rhythm
- Rhythm Maintains ISO Certification
- Close of Rights Issue
Later from Rhythm Biosciences
- Platform Expansion - Gastric Cancer Diagnostic Test Update
- Board Renewal / Composition Update
- 2nd Generation, ColoSTAT Multiplex Alpha Kit Outperforms
- Receipt of Research & Development Tax Incentive
- Strong Demand in Share Placement to Raise $3.5 million
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences